AUTHORS
Vipul Sheth, MD DM, Arnon Nagler I, MD2, Thibeault Ferhat Berland, PhD3, Francis Ayuketang Ayuk, MD4, Matthias Eder5, Tobias Gedde-Dahl6, Thomas Schroeder7, Hélène Labussière-Wallet8, Alienor Xhaard, MD9, Victoria Potter10, Raynier Devillier, PhD11, Johan A. Maertens, MD12, Francesca Kinsella, PhD13, Jurjen Versluis Sr, MD, PhD14, Vesa Lindström15, Alessandro Busca16, Edouard Forcade, MD, PhD17, Ali Bazarbachi18, Bipin Savani, MD19, Mohamad Mohty, MD, PhD20, Fabio Ciceri21, Jaime Sanz, MD, PhD22, Eolia Brissot, MD, PhD23
AFFILIATIONS
1 Rajiv Gandhi Cancer institute and research center, New Delhi, India
2 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel, Tel Hashomer, Israel
3 EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France, Paris, France
4 University Hospital Eppendorf, Hamburg, Germany
5 Hannover Medical School, Germany, Hannover, Germany
6 Oslo University Hospital, Rikshospitalet, Finland, Oslo, Finland
7 University Hospital, Essen, Germany, Essen, Germany
8 Centre Hospitalier Lyon Sud, Pierre Benite cedex, France, Lyon, France
9 BMT unit, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Saint-Louis Hospital, BMT Unit, Paris, France, Paris, France
10 Kings College hospital, London, United Kingdom
11 Programme de Transplantation & Therapie Cellulaire, Marseille, France, Marseille, France
12 University Hospital Gasthuisberg, Leuven, Belgium, Leuven, Belgium
13 Birmingham Centre for Cellular Therapy and Transplant, UK, Birmingham, United Kingdom
14 Erasmus MC Cancer Institute, Rotterdam, The Netherlands, Rotterdam, Netherlands
15 HUCH Comprehensive Cancer Center, Helsinki, Finland, Helsinki, Finland
16 S.C.V.D Trapianto di Cellule Staminali, Torino, Italy, Torino, Italy
17 CHU Bordeaux, Hôpital Haut-Levêque, Bordeaux, France, Bordeaux, France
18 Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon
19 Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Nashville, United States
20 Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France, Paris, France
21 Ospedale San Raffaele, Haematology and BMT, Milano, Italy, Milano, Italy
22 Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, Spain, Valencia, Spain
23 Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France, Paris, France
ABSTRACT
Background
Donor selection remains a key determinant of outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). Although donor age is widely recognized as an important consideration, whether its impact is consistent across different donor platforms and which additional donor characteristics independently influence outcomes in secondary acute myeloid leukemia (sAML) remain uncertain. We analyzed donor-specific variables within each donor platform separately to define clinically relevant donor selection criteria for sAML.
Methods
The study included adult patients (≥18 years) with sAML undergoing first allo-HCT in first complete remission between 2000 and 2023 reported to the ALWP/EBMT registry. Separate multivariable Cox regression models were constructed for each donor platform: matched sibling donor (MSD), unrelated donor (UD) and haploidentical donor (Haplo). Endpoints included overall survival (OS), leukemia free survival (LFS), Graft vs host disease (GVHD) free relapse free survival (GRFS), relapse incidence (RI), non-relapse mortality (NRM) and acute GVHD (aGVHD) and chronic GVHD (cGVHD).
Results
7,068 patients were included (917 Haplo, 2,290 MSD and 3,861 UD). Median follow-up for the entire cohort was 5.0 years. Among the three donor groups, UD were the youngest, (median 29.6 years; P<0.001), followed by Haplo (36.1 years). Transplantation from MSD was associated with the highest prevalence of CMV-seropositive donors (62.1%), whereas UD transplantation had the lowest (47.4%; P<0.001). Haplo recipients were more frequently CMV-seropositive (77.6%) and more commonly received bone marrow grafts, myeloablative conditioning (MAC) and PTCy-based GVHD prophylaxis. Recipient age, donor sex, Female (F) donor-to- male (M) recipient combinations, donor-recipient CMV serostatus, graft source, conditioning intensity and GVHD prophylaxis differed significantly across donor platforms (all P<0.001), whereas ELN-based cytogenetic risk was similar (P=0.10).
Within the UD cohort, increasing donor age (per 10-year increments) independently predicted inferior OS (HR 1.09, 95% CI 1.01–1.18, P=0.022) and higher NRM (HR 1.21, 95% CI 1.09–1.35, P<0.001). Older donor age was also associated with higher risk of aGVHD grade II-IV and III -IV (HR 1.16, 95% CI 1.05–1.27, P=0.002), and (HR 1.27, 95% CI 1.09–1.48, P=0.002), respectively, while no independent association was observed with LFS, GRFS, RI or cGVHD. F donor-to- M recipient combinations adversely affected LFS (HR 1.27, 95% CI 1.05–1.55, P=0.016), OS (HR 1.28, 95% CI 1.04–1.57, P=0.020) and NRM (HR 1.41, 95% CI 1.06–1.86, P=0.018). Recipient age, and adverse ELN- based cytogenetics risks, remained among the strongest independent predictors of transplantation outcomes including LFS, OS and GRFS, while earlier transplantation year predicted worse LFS and GRFS.
Within the Haplo cohort, increasing donor age independently predicted severe aGVHD (per 10 years; HR 1.21, 95% CI 1.01–1.45, P=0.039), while no independent association was observed with LFS, OS, GRFS, RI, or. NRM. Donor/recipient CMV serostatus was an independent prognostic factor for all grades cGVHD (negative to negative as referent group, HR 0.61, 95% CI 0.41–0.9, P=0.0013). Adverse cytogenetics risks, and RIC remained among the strongest independent predictors of high RI and poor OS, LFS and GRFS, whereas poor Karnofsky’s performance status (KPS) predicted higher NRM and lower LFS. Recipient age, adverse cytogenetic risks and earlier year of transplant were associated with increased risk of total cGVHD.
Within the MSD cohort, F donor to M recipient combinations adversely affected all grades cGVHD (HR 1.32, 95% CI 1.04–1.67, P=0.021). Recipient age, adverse cytogenetics risk, and earlier year of transplant remained among the strongest independent predictors of poor outcomes (LFS, OS, NRM, RI). MAC was associated with reduced RI but higher NRM. Total cGVHD incidence was reduced with time.
Conclusion
Donor selection in sAML should be individualized within each donor platform rather than based on donor type alone. Older donor age remains an important determinant of transplant outcomes in the UD setting, particularly with respect to survival and aGVHD, and in the Haplo settings for high grade aGVHD. F to M combinations was associated with worse survival in the UD setting, and a higher risk of cGVHD was observed with MSD. Finally, donor/recipient CMV serostatus was associated with risk of cGVHD in the Haplo setting.
DISCLOSURES
Vipul Sheth, MD DM: MicroCRISPR Pvt. Ltd - Research Funding; Immuneel Therapeutics Private Limited - Consultancy (Includes expert testimony); MicroCRISPR Pvt. Ltd - Consultancy (Includes expert testimony)